Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from Stifel Nicolaus

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reiterated by stock analysts at Stifel Nicolaus in a research note issued on Thursday,Benzinga reports. They presently have a $68.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $58.00. Stifel Nicolaus’ price target suggests a potential upside of 120.64% from the stock’s current price.

A number of other equities research analysts have also weighed in on the stock. Barclays boosted their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.20.

Celldex Therapeutics Trading Up 24.1%

Shares of Celldex Therapeutics stock opened at $30.82 on Thursday. The firm’s 50 day moving average is $25.51 and its 200 day moving average is $25.40. The firm has a market capitalization of $2.05 billion, a PE ratio of -9.12 and a beta of 1.24. Celldex Therapeutics has a 1 year low of $14.40 and a 1 year high of $31.00.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. As a group, research analysts anticipate that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Simplify Asset Management Inc. bought a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at $2,199,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Celldex Therapeutics during the second quarter valued at about $1,188,000. Corient Private Wealth LLC bought a new position in shares of Celldex Therapeutics during the 2nd quarter worth about $4,105,000. American Century Companies Inc. increased its position in Celldex Therapeutics by 24.7% in the 2nd quarter. American Century Companies Inc. now owns 779,985 shares of the biopharmaceutical company’s stock valued at $15,873,000 after buying an additional 154,664 shares in the last quarter. Finally, TFG Asset Management GP Ltd raised its stake in Celldex Therapeutics by 21.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 316,150 shares of the biopharmaceutical company’s stock worth $6,434,000 after buying an additional 55,150 shares during the period.

Trending Headlines about Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Celldex announced completion of enrollment in its global Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials for barzolvolimab in chronic spontaneous urticaria — 1,939 patients across 43 countries, the largest antihistamine‑refractory CSU program to date. This materially de‑risks the program and sets clear timing for upcoming readouts that could be major value drivers. EMBARQ enrollment release
• Positive Sentiment: Morgan Stanley reiterated a Buy on CLDX, highlighting early EMBARQ enrollment and a slate of 2026 data catalysts that, in the analyst’s view, create an attractive risk/reward. Analyst support likely bolstered investor confidence into the clinical milestone. Analyst note (TipRanks)
• Neutral Sentiment: Street consensus remains generally constructive: recent aggregator coverage shows an average rating around “Moderate Buy,” indicating broad analyst optimism but not unanimous conviction. Analyst consensus article
• Neutral Sentiment: Celldex filed its fourth‑quarter and full‑year 2025 results and corporate update; management provided program timing and other corporate details in the release. Investors should watch the corporate update for cash runway and milestone timelines. Financial results release
• Negative Sentiment: Q4 results missed expectations: Celldex reported ($1.22) EPS vs. consensus ($1.00) and revenue of $0.12M vs. $1.53M expected; margins and ROE were deeply negative. The beat/miss dynamics were unfavorable and highlight ongoing cash‑burn and execution risks until positive clinical data or partnering occurs. Earnings press release
• Neutral Sentiment: Reported short‑interest data for February is inconsistent/erroneous in the summary (shows 0 shares and NaN changes). There’s no reliable evidence here of a sizeable short squeeze or covering pressure based on that data alone. (Item flagged as data‑quality noisy.)

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.